STAT3 调节 CD8+ T 细胞分化和功能,在癌症和急性感染中发挥作用。
STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection.
机构信息
Institute for Immunology, Tsinghua University , Beijing, China.
Tsinghua-Peking Center for Life Sciences, Tsinghua University , Beijing, China.
出版信息
J Exp Med. 2023 Apr 3;220(4). doi: 10.1084/jem.20220686. Epub 2023 Jan 23.
In cancer, persistent antigens drive CD8+ T cell differentiation into exhausted progenitor (Texprog) and terminally exhausted (Texterm) cells. However, how the extrinsic and intrinsic regulatory mechanisms cooperate during this process still remains not well understood. Here, we found that STAT3 signaling plays essential roles in promoting intratumor Texterm cell development by enhancing their effector functions and survival, which results in better tumor control. In tumor microenvironments, STAT3 is predominantly activated by IL-10 and IL-21, but not IL-6. Besides, STAT3 also plays critical roles in the development and function of terminally differentiated effector CD8+ T cells in acute infection. Mechanistically, STAT3 transcriptionally promotes the expression of effector function-related genes, while it suppresses those expressed by the progenitor Tex subset. Moreover, STAT3 functions in collaboration with BATF and IRF4 to mediate chromatin activation at the effector gene loci. Thus, we have elucidated the roles of STAT3 signaling in terminally differentiated CD8+ T cell development, especially in cancer, which benefits the development of more effective immunotherapies against tumors.
在癌症中,持续存在的抗原会促使 CD8+ T 细胞分化为耗竭祖细胞(Texprog)和终末耗竭(Texterm)细胞。然而,在这个过程中,外在和内在的调节机制如何合作仍不太清楚。在这里,我们发现 STAT3 信号通路通过增强效应功能和存活来促进肿瘤内 Texterm 细胞的发育,从而更好地控制肿瘤。在肿瘤微环境中,STAT3 主要由 IL-10 和 IL-21 激活,而不是 IL-6。此外,STAT3 在急性感染中也对终末分化的效应 CD8+ T 细胞的发育和功能发挥着关键作用。在机制上,STAT3 转录促进效应功能相关基因的表达,同时抑制祖细胞 Tex 亚群表达的基因。此外,STAT3 与 BATF 和 IRF4 合作,介导效应基因座的染色质激活。因此,我们阐明了 STAT3 信号通路在终末分化的 CD8+ T 细胞发育中的作用,特别是在癌症中的作用,这有利于开发更有效的针对肿瘤的免疫疗法。
相似文献
Front Immunol. 2021-2-2
Cancers (Basel). 2021-3-12
引用本文的文献
Signal Transduct Target Ther. 2025-8-30
NPJ Biofilms Microbiomes. 2025-8-21
Invest New Drugs. 2025-8-16
Nat Nanotechnol. 2025-8-11
Nat Immunol. 2025-7-23
本文引用的文献
Nat Rev Immunol. 2022-4